Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) Invested Capital (2016 - 2025)

Historic Invested Capital for Haemonetics (HAE) over the last 16 years, with Q4 2025 value amounting to $2.1 billion.

  • Haemonetics' Invested Capital rose 1305.01% to $2.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.1 billion, marking a year-over-year increase of 1305.01%. This contributed to the annual value of $2.0 billion for FY2025, which is 4061.47% up from last year.
  • According to the latest figures from Q4 2025, Haemonetics' Invested Capital is $2.1 billion, which was up 1305.01% from $2.1 billion recorded in Q3 2025.
  • In the past 5 years, Haemonetics' Invested Capital registered a high of $2.1 billion during Q4 2025, and its lowest value of $974.6 million during Q3 2021.
  • Moreover, its 5-year median value for Invested Capital was $1.4 billion (2023), whereas its average is $1.5 billion.
  • As far as peak fluctuations go, Haemonetics' Invested Capital tumbled by 98.83% in 2022, and later skyrocketed by 4061.47% in 2025.
  • Over the past 5 years, Haemonetics' Invested Capital (Quarter) stood at $991.6 million in 2021, then increased by 27.82% to $1.3 billion in 2022, then increased by 13.41% to $1.4 billion in 2023, then soared by 31.46% to $1.9 billion in 2024, then grew by 13.05% to $2.1 billion in 2025.
  • Its Invested Capital was $2.1 billion in Q4 2025, compared to $2.1 billion in Q3 2025 and $2.1 billion in Q2 2025.